Urinary retention and post-void residual urine in men: separating truth from tradition.

[1]  S. Kaplan,et al.  Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. , 2008, The Journal of urology.

[2]  C. Roehrborn,et al.  MP-20.23: Tolterodine extended release (TER) and/or Tamsulosin (TAM) in men with lower urinary tract symptoms (LUTS) including overactive bladder (OAB): effects of serum prostate-specific antigen (PSA) level , 2007 .

[3]  C. Roehrborn,et al.  MP-20.24: Tolterodine extended release (TER) and/or Tamsulosin (TAM) in men with lower urinary tract symptoms (LUTS) including overactive bladder (OAB): effects of prostate size , 2007 .

[4]  J. Abarbanel,et al.  Impaired detrusor contractility in community-dwelling elderly presenting with lower urinary tract symptoms. , 2007, Urology.

[5]  C. Roehrborn.  Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. , 2007, BJU international.

[6]  C. Roehrborn.  Post-Void Residual Urine Volume Is Not a Good Predictor of the Need for Invasive Therapy Among Patients With Benign Prostatic Hyperplasia , 2006 .

[7]  G. Kuchel,et al.  Detrusor Underactivity: Clinical Features and Pathogenesis of an Underdiagnosed Geriatric Condition , 2006, Journal of the American Geriatrics Society.

[8]  C. Roehrborn,et al.  Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. , 2006, JAMA.

[9]  Jan van der Meulen,et al.  Incidence of primary and recurrent acute urinary retention between 1998 and 2003 in England. , 2006, The Journal of urology.

[10]  C. Roehrborn,et al.  Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. , 2006, The Journal of urology.

[11]  M. Emberton.  Definition of at‐risk patients: dynamic variables , 2006, BJU international.

[12]  C. Roehrborn.  Definition of at‐risk patients: baseline variables , 2006, BJU international.

[13]  J. Fitzpatrick,et al.  Management of acute urinary retention , 2006, BJU international.

[14]  K. Yorukoglu,et al.  Relation between acute urinary retention, chronic prostatic inflammation and accompanying elevated prostate-specific antigen , 2006, Scandinavian journal of urology and nephrology.

[15]  P. Abrams,et al.  The natural history of lower urinary tract dysfunction in men: minimum 10‐year urodynamic follow‐up of untreated bladder outlet obstruction , 2005, BJU international.

[16]  P. Gallien,et al.  Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[17]  A. Rule,et al.  Longitudinal changes in post-void residual and voided volume among community dwelling men. , 2005, The Journal of urology.

[18]  R. Sakakibara,et al.  Meningitis–retention syndrome , 2005, Journal of Neurology.

[19]  R. Pickard,et al.  A prospective randomized trial comparing transurethral prostatic resection and clean intermittent self‐catheterization in men with chronic urinary retention , 2005, BJU international.

[20]  R. Roberts,et al.  Limitations of using outcomes in the placebo arm of a clinical trial of benign prostatic hyperplasia to quantify those in the community. , 2005, Mayo Clinic proceedings.

[21]  R. Roberts,et al.  Original ArticleLimitations of Using Outcomes in the Placebo Arm of a Clinical Trial of Benign Prostatic Hyperplasia to Quantify Those in the Community , 2005 .

[22]  B. Stricker,et al.  Low incidence of acute urinary retention in the general male population: the triumph project. , 2005, European urology.

[23]  C. Roehrborn,et al.  1638: Baseline Post Void Residual Urine Volume as a Predictor of Urinary Outcomes in Men with BPH in the MTOPS Study , 2005 .

[24]  C. Roehrborn,et al.  1277: The Impact of Acute or Chronic Inflammation in Baseline Biopsy on the Risk of Clinical Progression of BPH: Results from the MTOPS Study , 2005 .

[25]  J. Logie,et al.  Incidence, prevalence and management of lower urinary tract symptoms in men in the UK , 2005, BJU international.

[26]  R. Sakakibara,et al.  Meningitis-retention syndrome. An unrecognized clinical condition. , 2005, Journal of Neurology.

[27]  C. Roehrborn,et al.  Efficacy and Safety of Long-Term Treatment with the Dual 5α-Reductase Inhibitor Dutasteride in Men with Symptomatic Benign Prostatic Hyperplasia , 2004 .

[28]  P. Boyle,et al.  5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. , 2004, European urology.

[29]  P. Abrams,et al.  The natural history of lower urinary tract dysfunction in men: the influence of detrusor underactivity on the outcome after transurethral resection of the prostate with a minimum 10‐year urodynamic follow‐up , 2004, BJU international.

[30]  C. Roehrborn,et al.  Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. , 2004, The Journal of urology.

[31]  C. Roehrborn,et al.  The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. , 2003, The New England journal of medicine.

[32]  E. McGuire,et al.  Obstructive uropathy induced bladder dysfunction can be reversible: bladder compliance measures before and after treatment. , 2003, The Journal of urology.

[33]  C. Roehrborn.  5-alpha-Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia. , 2003, Reviews in urology.

[34]  C. Roehrborn.  5-α-Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia , 2003 .

[35]  A. Tubaro,et al.  Early Treatment of Benign Prostatic Hyperplasia , 2003, Drugs & aging.

[36]  C. Roehrborn,et al.  Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. , 2002, European urology.

[37]  R. Soundararajan,et al.  Unusual presentation of acute renal failure from obstructive uropathy. , 2002, Journal of Urology.

[38]  C. Roehrborn,et al.  Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. , 2001, Urology.

[39]  Cespedes Rd.  Treatment options for outlet obstruction following anti-incontinence surgery in females. , 2001 .

[40]  C. Roehrborn,et al.  Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin. , 2001, Urology.

[41]  R. Hartung.  Do Alpha-Blockers Prevent the Occurrence of Acute Urinary Retention? , 2001, European Urology.

[42]  V. Rivera,et al.  Urodynamic pattern changes in multiple sclerosis. , 2001, Urology.

[43]  A. Tubaro.  Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. , 2001 .

[44]  M. Marberger,et al.  Prostate Volume and Serum Prostate–Specific Antigen as Predictors of Acute Urinary Retention , 2000, European Urology.

[45]  S. Kaplan,et al.  Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group. , 2000, Urology.

[46]  E. Rimm,et al.  Incidence rates and risk factors for acute urinary retention: the health professionals followup study. , 1999, The Journal of urology.

[47]  C. Roehrborn,et al.  Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. , 1999, Urology.

[48]  P. Boyle,et al.  Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. , 1999, Urology.

[49]  M. Drake,et al.  Drug-Induced Bladder and Urinary Disorders , 1998, Drug safety.

[50]  M. Marberger.  Long-Term Effects of Finasteride in Patients with Benign Prostatic Hyperplasia: A Double-Blind, Placebo-Controlled, Multicenter Study , 1998 .

[51]  A. Elbadawi.  Voiding dysfunction in benign prostatic hyperplasia: trends, controversies and recent revelations. I. Symptoms and urodynamics. , 1998, Urology.

[52]  A. Elbadawi.  Voiding dysfunction in benign prostatic hyperplasia: trends, controversies and recent revelations. II. Pathology and pathophysiology. , 1998, Urology.

[53]  E. McGuire,et al.  Transvaginal urethrolysis for urethral obstruction after anti-incontinence surgery. , 1998, The Journal of urology.

[54]  J. Nickel.  Placebo therapy of benign prostatic hyperplasia: a 25-month study. Canadian PROSPECT Study Group. , 1998, British journal of urology.

[55]  M. Marberger.  Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group. , 1998, Urology.

[56]  R. Roberts,et al.  Natural history of prostatism: risk factors for acute urinary retention. , 1997, The Journal of urology.

[57]  R. Sakakibara,et al.  Micturitional disturbance in acute disseminated encephalomyelitis (ADEM). , 1996, Journal of the autonomic nervous system.

[58]  W. Mebust.  Symptoms and urodynamics. , 1995, Journal of Urology.

[59]  J. Gleave,et al.  Prognosis for recovery of bladder function following lumbar central disc prolapse. , 1990, British journal of neurosurgery.

[60]  D. Neal,et al.  Relationship between detrusor function and residual urine in men undergoing prostatectomy. , 1987, British journal of urology.

[61]  D. Neal,et al.  Relationship between voiding pressures, symptoms and urodynamic findings in 253 men undergoing prostatectomy. , 1987, British journal of urology.

[62]  P. Klarskov,et al.  Symptoms and signs predictive of the voiding pattern after acute urinary retention in men. , 1987, Scandinavian journal of urology and nephrology.

[63]  P. Abrams,et al.  Urodynamic findings in chronic retention of urine and their relevance to results of surgery. , 1978, British medical journal.